Cell Source, Inc. (CLCS)
USD 0.28
(-16.67%)
USD 0.28
(-16.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.8 Million USD | 21.18% |
| 2022 | 13.04 Million USD | 28.64% |
| 2021 | 10.13 Million USD | 20.72% |
| 2020 | 8.39 Million USD | 43.42% |
| 2019 | 5.85 Million USD | 17.46% |
| 2018 | 4.98 Million USD | -2.03% |
| 2017 | 5.08 Million USD | -21.15% |
| 2016 | 6.45 Million USD | 5.35% |
| 2015 | 6.12 Million USD | 56.8% |
| 2014 | 3.9 Million USD | 53104.86% |
| 2013 | 7343.00 USD | 44.01% |
| 2012 | 5099.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 16.83 Million USD | 6.52% |
| 2024 Q2 | 17.74 Million USD | 5.42% |
| 2023 Q4 | 15.8 Million USD | -2.9% |
| 2023 Q2 | 15.3 Million USD | 5.92% |
| 2023 Q1 | 14.45 Million USD | 10.8% |
| 2023 Q3 | 16.27 Million USD | 6.34% |
| 2023 FY | 15.8 Million USD | 21.18% |
| 2022 Q2 | 10.81 Million USD | 5.23% |
| 2022 Q3 | 12.31 Million USD | 13.91% |
| 2022 FY | 13.04 Million USD | 28.64% |
| 2022 Q1 | 10.27 Million USD | 1.32% |
| 2022 Q4 | 13.04 Million USD | 5.92% |
| 2021 Q4 | 10.13 Million USD | -8.22% |
| 2021 Q3 | 11.04 Million USD | 6.9% |
| 2021 Q2 | 10.33 Million USD | 10.45% |
| 2021 FY | 10.13 Million USD | 20.72% |
| 2021 Q1 | 9.35 Million USD | 11.4% |
| 2020 Q4 | 8.39 Million USD | 16.2% |
| 2020 Q2 | 6.61 Million USD | 3.46% |
| 2020 Q3 | 7.22 Million USD | 9.36% |
| 2020 FY | 8.39 Million USD | 43.42% |
| 2020 Q1 | 6.38 Million USD | 9.1% |
| 2019 Q2 | 5.23 Million USD | 1.22% |
| 2019 FY | 5.85 Million USD | 17.46% |
| 2019 Q1 | 5.17 Million USD | 3.7% |
| 2019 Q4 | 5.85 Million USD | -2.26% |
| 2019 Q3 | 5.99 Million USD | 14.5% |
| 2018 Q3 | 6.21 Million USD | 4.76% |
| 2018 FY | 4.98 Million USD | -2.03% |
| 2018 Q1 | 5.73 Million USD | 12.75% |
| 2018 Q2 | 5.92 Million USD | 3.33% |
| 2018 Q4 | 4.98 Million USD | -19.72% |
| 2017 FY | 5.08 Million USD | -21.15% |
| 2017 Q1 | 5.61 Million USD | -13.07% |
| 2017 Q2 | 5.48 Million USD | -2.26% |
| 2017 Q3 | 5.71 Million USD | 4.21% |
| 2017 Q4 | 5.08 Million USD | -10.94% |
| 2016 Q2 | 7.48 Million USD | 7.44% |
| 2016 FY | 6.45 Million USD | 5.35% |
| 2016 Q3 | 8.09 Million USD | 8.2% |
| 2016 Q4 | 6.45 Million USD | -20.26% |
| 2016 Q1 | 6.96 Million USD | 13.65% |
| 2015 Q3 | 5.85 Million USD | 11.96% |
| 2015 Q2 | 5.23 Million USD | 10.18% |
| 2015 Q1 | 4.74 Million USD | 21.52% |
| 2015 FY | 6.12 Million USD | 56.8% |
| 2015 Q4 | 6.12 Million USD | 4.61% |
| 2014 Q4 | 3.9 Million USD | 56.77% |
| 2014 FY | 3.9 Million USD | 53104.86% |
| 2014 Q2 | 2.76 Million USD | 101348.64% |
| 2014 Q1 | 2724.00 USD | -62.9% |
| 2014 Q3 | 2.49 Million USD | -9.82% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 7343.00 USD | 67.53% |
| 2013 FY | 7343.00 USD | 44.01% |
| 2013 Q3 | 4383.00 USD | 0.0% |
| 2012 FY | 5099.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -57519.342% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -66.985% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 78.189% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1854.356% |
| Rebus Holdings, Inc. | 5.24 Million USD | -201.54% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 73.215% |
| Qrons Inc. | 1.48 Million USD | -961.77% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -1189.068% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 78.902% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -35264.941% |
| Skye Bioscience, Inc. | 14.07 Million USD | -12.326% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 70.347% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -64.962% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -3649.505% |
| SQZ Biotechnologies Company | 50.03 Million USD | 68.411% |
| Intellipharmaceutics International Inc. | 12 Million USD | -31.626% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -310.412% |
| Mesoblast Limited | 188.44 Million USD | 91.612% |
| Marizyme, Inc. | 26.67 Million USD | 40.745% |
| Genus plc | 485 Million USD | 96.741% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -170.541% |
| Pharming Group N.V. | 244.07 Million USD | 93.524% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -686.353% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -528.166% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -315.966% |
| ContraFect Corporation | 32.53 Million USD | 51.41% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -697.792% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -312.962% |
| IMV Inc. | 37.93 Million USD | 58.33% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -34.203% |
| MultiCell Technologies, Inc. | 1617.67 USD | -977028.463% |
| ONE Bio Corp. | 27.49 Million USD | 42.512% |
| Accustem Sciences Inc. | 1.07 Million USD | -1364.617% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 79.582% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -647.338% |
| Q BioMed Inc. | 8.13 Million USD | -94.354% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 80.941% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -207.163% |
| Biomind Labs Inc. | 1.49 Million USD | -954.757% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 86.686% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -74.811% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 14.11% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1002.388% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -11024.047% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -7759.501% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -175.099% |
| GB Sciences, Inc. | 5.41 Million USD | -191.768% |
| Alpha Cognition Inc. | 7.16 Million USD | -120.617% |
| HST Global, Inc. | 593.59 Thousand USD | -2562.888% |
| CSL Limited | 18.62 Billion USD | 99.915% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1155.305% |
| Halberd Corporation | 728.71 Thousand USD | -2069.11% |
| Enzolytics Inc. | 365.26 Million USD | 95.673% |
| Agentix Corp. | 2.51 Million USD | -529.61% |
| Resverlogix Corp. | 67.39 Million USD | 76.547% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1784.597% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 96.448% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -822.212% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 36.124% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -32.795% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -331.269% |
| AVAX Technologies, Inc. | 3.99 Million USD | -295.787% |
| Zenith Capital Corp. | 27.56 Thousand USD | -57235.101% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.808% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -6523.276% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -323.284% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2221.669% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -482.921% |
| Kadimastem Ltd | 3.5 Million USD | -350.993% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -23517.138% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 68.553% |
| BioStem Technologies, Inc. | 15.9 Million USD | 0.616% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -3301.495% |
| LadRx Corporation | 2.2 Million USD | -618.315% |
| Regen BioPharma, Inc. | 5.45 Million USD | -189.627% |
| Regen BioPharma, Inc. | 5.45 Million USD | -189.627% |
| NovAccess Global Inc. | 7.86 Million USD | -101.085% |
| Affymax, Inc. | 8.87 Million USD | -78.184% |
| Itoco Inc. | 1.65 Million USD | -856.157% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -670.471% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -161.311% |
| Mobile Lads Corp. | 1.31 Million USD | -1103.407% |
| CytoDyn Inc. | 127.89 Million USD | 87.641% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -37716.01% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -909.126% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -43.108% |
| SYBLEU INC | 681.41 Thousand USD | -2219.697% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -159.046% |
| International Stem Cell Corporation | 5.27 Million USD | -199.54% |
| Bioxytran, Inc. | 3.24 Million USD | -386.435% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2425.805% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -242.35% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 61.443% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 29.006% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -680.429% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -188.549% |
| Neutra Corp. | 973.52 Thousand USD | -1523.651% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 45.522% |
| PureTech Health plc | 125.58 Million USD | 87.413% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -320.713% |
| IXICO plc | 1.9 Million USD | -731.804% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 23.003% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 84.702% |
| CSL Limited | 18.62 Billion USD | 99.915% |
| Cellectis S.A. | 249.36 Million USD | 93.661% |